AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Recently, there has been a lot of interest by using nanobodies (heavy chain-only antibodies produced naturally from the Camelidae) as targeting molecules for molecular imaging, especially for the nuclear medicine imaging. A radiolabeled method that generates a homogeneous product is of utmost importance in radiotracer development for the nuclear medicine imaging. The conventional method for the radiolabeling of nanobodies is non-specifically, which conjugates the radioisotope chelating group to the side chain ɛ-amine group of lysine or sulfhydryl of cysteine of nanobodies, with a shortcoming of produce of the heterogeneous radiotracer. Here we describe a method for the site-specific radioisotope 99mTc labeling of nanobodies by transpeptidase Sortase A. The radiolabeling process includes two steps: first step, NH2-GGGGK(HYNIC)-COOH peptide (GGGGK = NH2-Gly-Gly-Gly-Gly-Lys-COOH, HYNIC = 6-hydrazinonicotinyl) was labeled with 99mTc to obtain GGGGK-HYNIC-99mTc; second step, Sortase A catalyzes the formation of a new peptide bond between the peptide motif LPETG (NH2-Leu-Pro-Glu-Thr-Gly-COOH) expressed C-terminally on the nanobody and the N-terminal of GGGGK-HYNIC-99mTc. After a simple purification process, homogeneous single-conjugated and stable 99mTc-labeled nanobodies were obtained in >50% yield. This approach demonstrates that the Sortase A-mediated conjugation is a valuable strategy for the development of site-specifically 99mTc-labeled nanobodies.
Agarwal P, Bertozzi CR (2015) Site-specific antibody–drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem 26(2): 176−192
Alt K, Paterson BM, Ardipradja K, Schieber C, Buncic G, Lim B, Poniger SS, Jakoby B, Wang X, O’Keefe GJ (2014) Single-chain antibody conjugated to a cage amine chelator and labeled with positron-emitting copper-64 for diagnostic imaging of activated platelets. Mol Pharm 11(8): 2855−2863
Biechlin ML, d'Hardemare AdM, Fraysse M, Gilly FN, Bonmartin A (2005) Improvement in radiolabelling proteins with the 99mTc‐tricarbonyl‐core [99mTc(CO)3]+, by thiol‐derivatization with iminothiolane: application to γ‐globulins and annexin V. J Labelled Compd Rad 48(12): 873−885
Feng Y, Zhou Z, McDougald D, Meshaw RL, Vaidyanathan G, Zalutsky MR (2020) Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent. Nucl Med Biol 62: 171−183
Gao H, Wu Y, Shi J, Zhang X, Liu T, Hu B, Jia B, Wan Y, Liu Z, Wang F (2020) Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. J Immunother cancer 8(2): e001156
Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, Bendahman N, Hammers R (1993) Naturally occurring antibodies devoid of light chains. Nature 363(6428): 446−448
Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S (2013) Nanobodies and their potential applications. Nanomedicine 8(6): 1013−1026
Jia B, Shi J, Yang Z, Xu B, Liu Z, Zhao H, Liu S, Wang F (2006) 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin αvβ3 expression. Bioconjug Chem 17(4): 1069−1076
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P (2016) Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med 57(1): 27−33
Liu M, Li L, Jin D, Liu Y (2021) Nanobody — A versatile tool for cancer diagnosis and therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol 13(4): e1697
Luo Q, Yang G, Gao H, Wang Y, Luo C, Ma X, Gao Y, Li X, Zhao H, Jia B, Shi J, Wang F (2020) An integrin alpha 6-targeted radiotracer with improved receptor binding affinity and tumor uptake. Bioconjug Chem 31(5): 1510−1521
Lv G, Sun X, Qiu L, Sun Y, Li K, Liu Q, Zhao Q, Qin S, Lin J (2020) PET imaging of tumor PD-L1 expression with a highly specific nonblocking single-domain antibody. J Nucl Med 61(1): 117−122
Massa S, Vikani N, Betti C, Ballet S, Vanderhaegen S, Steyaert J, Descamps B, Vanhove C, Bunschoten A, van Leeuwen FW (2016) Sortase A-mediated site-specific labeling of camelid single-domain an tibody-fragments: a versatile strategy for multiple molecular imaging modalities. Contrast Media Mol Imaging 11(5): 328−339
Mazmanian SK, Liu G, Ton-That H, Schneewind O (1999) Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 285(5428): 760−763
McMahon C, Baier AS, Pascolutti R, Wegrecki M, Zheng S, Ong JX, Erlandson SC, Hilger D, Rasmussen SG, Ring AM (2018) Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct Mol Biol 25(3): 289−296
Oliveira S, Heukers R, Sornkom J, Kok RJ, en Henegouwen PMvB (2013) Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release 172(3): 607−617
Paterson BM, Alt K, Jeffery CM, Price RI, Jagdale S, Rigby S, Williams CC, Peter K, Hagemeyer CE, Donnelly PS (2014) Enzyme-mediated site-specific bioconjugation of metal complexes to proteins: Sortase-mediated coupling of copper-64 to a single-chain antibody. Angew Chem Int Ed Engl 53(24): 6115−6119
Popp MW, Antos JM, Grotenbreg GM, Spooner E, Ploegh HL (2007) Sortagging: a versatile method for protein labeling. Nat Chem Biol 3(11): 707−708
Rashidian M, Wang L, Edens JG, Jacobsen JT, Hossain I, Wang Q, Victora GD, Vasdev N, Ploegh H, Liang SH (2016) Enzyme-mediated modification of single-domain antibodies for imaging modalities with different characteristics. Angew Chem Int Ed Engl 128(2): 538−543
Xing Y, Chand G, Liu C, Cook GJ, O’Doherty J, Zhao L, Wong NC, Meszaros LK, Ting HH, Zhao J (2019) Early phase I study of a 99mTc-labeled anti–programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non–small cell lung cancer. J Nucl Med 60(9): 1213−1220
Yang EY, Shah K (2020) Nanobodies: next generation of cancer diagnostics and therapeutics. Front Oncol 10: 1182−1197
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
